Business Wire

Velodyne Lidar’s Groundbreaking Sensors Power Kaarta Mobile Mapping

Share

Velodyne Lidar, Inc. today announced Kaarta has included Velodyne’s smart, powerful lidar technology in Kaarta’s new Stencil 2-32 ground surface mapping solution. Equipped with Velodyne lidar, Stencil 2-32 accurately scans ground level surfaces, mapping items such as curbs, manholes, signs, poles, and other features at a fraction of the cost of traditional mobile mapping systems. The Stencil platform helps enable city planning for infrastructure improvements as well as parking and traffic management.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190716005210/en/

Kaarta’s new Stencil 2-32 ground surface mapping solution includes Velodyne’s smart, powerful lidar technology. (Photo: Business Wire)

Kaarta’s new Stencil 2-32 ground surface mapping solution includes Velodyne’s smart, powerful lidar technology. (Photo: Business Wire)

The 3D data generated by Stencil 2-32 can be utilized for a range of applications including BIM modeling, geospatial data analytics, and cataloging tools. For example, Allvision uses Stencil 2-32 along with data from an autonomous vehicle developer to conduct curb occupancy analysis in Pittsburgh’s Strip District, an area known for high on-street parking demands. Called Allvision Parkview, the solution allows city planners to monitor parking behavior to improve transportation planning and curb management.

“The addition of Stencil 2-32 to Kaarta’s product line further extends the range of mapping applications for mobile lidar scanning,” said Kevin Dowling, Ph.D., CEO, Kaarta. “The low noise, long range, and field of view of Velodyne’s compact lidar sensors allow us to create systems with immense versatility, accuracy, and speed – from capture to answer.”

Stencil integrates 3D mapping and real-time position estimation to create capabilities not possible with fixed-base scanning systems. Stencil 2-32 incorporates the Velodyne HDL-32E lidar sensor, which provides a range of 100 meters and a data rate of 720,000 points per second. Kaarta leverages advanced robotics technology that combines input from multiple sensors – lidar, visual odometry, and inertial measurement unit (IMU) – and processes that data in real time. For some applications, the data can be enhanced with Global Navigation Satellite System (GNSS) positioning and wheel odometry sensors.

“Velodyne lidar and Kaarta’s advanced 3D mapping and localization algorithms are a phenomenal combination, creating a portable system for fast and easy detailed surface mapping,” said Aaron Morris, Founder and CEO, Allvision. “The ability to rapidly gather accurate and up-to-date geospatial information has countless applications.”

Stencil 2-32 is the newest member of Kaarta’s Stencil product line which also includes Stencil 2-16, a versatile low-cost mobile mapping platform that uses the Velodyne Puck™ sensor. Its ease of use, breadth of applications, and streamlined workflow make the system well-suited for infrastructure inspectors, surveyors, engineers, architects, facilities planners, security personnel, and more.

“Kaarta and Allvision demonstrate how to tap the full potential of Velodyne’s rich computer perception data for an innovative solution to inventory, track, and monitor assets for accurate future planning and management,” said Mike Jellen, President and CCO, Velodyne Lidar.

About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Founded in 1983 and headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. In 2005, Velodyne’s Founder and CEO, David Hall, invented real-time surround view lidar systems, revolutionizing perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Puck™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.

About Kaarta
Kaarta is the innovator of real-time mobile 3D reality capture, mapping complex environments with unprecedented speed, fidelity and ease. Kaarta works without external signal infrastructure such as GPS or Wi-Fi. Kaarta’s patent-pending technology, rooted in advanced robotics, accurately transforms the real world into 3D digital twins, streamlining workflow, reducing time, lowering cost, and providing a new level of understanding of spaces for humans and autonomous machines alike. Now the spectrum of stakeholders across architecture, engineering, construction, and property owner/operators, facilities planners and managers, and mobile robotics developers can work from the same truth. Additional information is available at www.kaarta.com.

Contact information

Sean Dowdall
Landis Communications Inc. for Velodyne Lidar, Inc.
(415) 286-7121
velodyne@landispr.com

Kathy Pattison
Kaarta
(617) 515-6946
media@kaarta.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria24.1.2020 06:00:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), as well as the ongoing Phase II (PVO-1A-202/204) extension studies. In both the Phase III and Phase II extension studies, palovarotene is dosed both chronically (daily) and episodically (during flare-ups). The decision to pause dosing patients in the trial is based on results of a futility analysis reviewed by the Independent Data Monitoring Committee (IDMC) as part of the prespecified interim analysis. The results of a futility analysis indicated that the Phase III FOP trial was unlikely to meet its primary efficacy endpoint (annualized change in new HO volume as compared with Natural History Studyi) upon completion. Despite the results of the prespecified interim analysis, signals of encouraging therapeutic activity w

Amazentis Announces the Launch of Timeline™ Cellular Nutrition at the World Economic Forum in Davos23.1.2020 20:56:00 CETPress release

Amazentis announces the debut of Timeline, a next generation nutrition product designed to promote healthy aging, as part of the Swiss Food & Nutrition Valley in the House of Switzerland at the World Economic Forum in Davos, Switzerland. Given the increase in the aging population globally -- according to a 2019 Deutsche Bank study, there are more people on Earth older than sixty five than younger than five for the first time -- it is imperative for consumers to take proactive measures to maintain a high quality of life, for as long as they live. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005820/en/ (Photo: Business Wire) Timeline contains the proprietary nutrient Mitopure™, a highly pure form of Urolithin A. After a decade of rigorous research by leading scientists around the world, Mitopure has been shown to help counter age-associated cellular and muscular decline by revitalizing the mitochondria, the powerplants

Lionbridge Names Corinne Saunders as Managing Director, EMEA23.1.2020 18:00:00 CETPress release

Today, Lionbridge, a global leader in localization and data training services, announced that former Wolters Kluwer executive Corinne Saunders has joined the company as managing director of EMEA. Lionbridge currently has 51 offices in 26 countries around the world; Saunders will oversee EMEA sales, account management, and marketing operations. “Europe represents a large portion of our overall business and will continue to be a growth area for our AI and localization businesses. I am very happy that Corinne is coming onboard to lead our efforts across EMEA,” says Lionbridge Chief Executive Officer John Fennelly. “Throughout her career, she’s shown an exceptional ability for driving innovation and understanding customer needs.” While at Wolters Kluwer, Saunders served as chief executive officer for emerging and developing markets. Saunders will work from Brussels, Belgium. About Lionbridge Lionbridge partners with brands to break barriers and build bridges all over the world. For more th

President Bill Clinton to Keynote 2020 World Patient Safety, Science & Technology Summit23.1.2020 17:34:00 CETPress release

President Bill Clinton, the 42nd President of the United States, will be the closing keynote speaker at the Patient Safety Movement Foundation’s 2020 World Patient Safety, Science & Technology Summit. The 8th annual Summit will be held in Huntington Beach, California, beginning with a Pre-Summit Symposium on Thursday, March 5th. At the 2020 Summit, hospital leaders, medical and information technology innovators, patient advocates, policy makers and government officials collaborate and discuss best practices solutions to eliminate preventable patient deaths in hospitals around the world. The event is co-convened with the International Society for Quality in Health Care (ISQua), the American Society of Anesthesiologists and the European Society of Anaesthesiology. The 2020 Summit is scheduled for March 5 – 7th, 2020, at the Waterfront Beach Resort in Huntington Beach, California. For more information about the 2020 World Patient Safety, Science & Technology Summit, visit http://patientsa

Covantis initiative announces technology partner - ConsenSys23.1.2020 15:00:00 CETPress release

The founding members of the Covantis initiative, which aims to modernize global trade operations, have announced the selection of ConsenSys, a market-leading Ethereum blockchain technology company, as the lead technology partner to develop its transformative platform. “The founders set up a robust selection process, including a two week hackathon, to ensure that we chose the right technology partner to meet our industry’s needs,” said Stefano Rettore, independent advisor to the project. “ConsenSys presented prototypes that demonstrated excellence in its field and has a track record of using blockchain technology to digitize processes in the commodity trade finance industry. We are confident this partnership will allow us to build a first-class product, centered around unparalleled functionality, security and privacy.” ConsenSys will leverage its enterprise-ready blockchain solutions and services, including PegaSys Orchestrate, Kaleido and MythX to build the blockchain network on Ethere

PathoQuest’s Paris-based Facility Obtains GLP Certificate for the Company’s Biologics Genomic Quality Control Testing Service23.1.2020 13:00:00 CETPress release

PathoQuest, a company with expertise in genomic analysis, announced today that it has received GLP certificate of conformity following a successful inspection by the French National Agency for Medicine and Health Products Safety (ANSM). PathoQuest is the first company in France to have a facility receive such a GLP certificate from the ANSM for advanced, Next Generation Sequencing viral safety testing (“high-throughput sequencing detection of incidental replicative virus test in eukaryote cells”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005345/en/ (Graphic: Business Wire) Violaine Melen, PathoQuest’s Chief of Quality Assurance and Regulatory Affairs, stated “we are really proud of the achievement of this key regulatory milestone. Receiving this GLP certificate is the confirmation of the quality of our entire process, from receipt of a biological sample to report generation, inclusive of bioinformatics analysis a